

4. (Amended) Method as claimed in claim 1, characterized in that a second cytokeratin-specific binding molecule is used.

5. (Amended) Method as claimed in claim 1, characterized in that the binding molecules are indirectly labeled.

6. (Amended) Method as claimed in claim 1, characterized in that the binding molecules are directly labeled.

7. (Amended) Method as claimed in claim 1, characterized in that the sample is evaluated quantitatively by a confocal laser scanning microscope or by a fluorescence microscope.

8. (Amended) Method as claimed in claim 1 characterized in that the sample is evaluated by parallel or/and sequential determination of the fluorescence of the various labeling groups.

9. (Amended) Method as claimed in claim 1, additionally comprising a characterization of cells identified by reaction with the binding molecules.

12. (Amended) Use of the method as claimed in claim 1 to detect micrometastases in biological samples.

16. (Amended) Use as claimed in claim 14 in an ELISA.

17. (Amended) Use as claimed in claim 14 in a double-fluorescence detection method.

18. (Amended) Use as claimed in claim 13, characterized in that the antibody is selected from the monoclonal antibody IIIF10, fragments thereof or antibodies and antibody fragments having an equivalent binding specificity.